Virtu Financial LLC Akari Therapeutics PLC Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$0.16 - $0.22 $2,629 - $3,616	16,437 New	16,437 $3,000
Q4 2022 Feb 15, 2023	BUY	$0.41 - $12.8 $4,301 - $134,284	10,491 New	10,491 $5,000
Q2 2022 Aug 09, 2022	SELL	$0.95 - $1.22 $15,842 - $20,344	-16,676 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.09 - $1.53 $18,176 - $25,514	16,676 New	16,676 $20,000
Q3 2020 Dec 11, 2020	SELL	$1.58 - $2.37 $28,643 - $42,965	-18,129 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$1.16 - $2.61 $21,029 - $47,316	18,129 New	18,129 $40,000
Q4 2019 Feb 04, 2020	SELL	$1.69 - $2.16 $52,599 - $67,227	-31,124 Closed	0 $0
Q3 2019 Nov 20, 2019	BUY	$1.69 - $2.92 $34,192 - $59,077	20,232 Added 185.75%	31,124 $53,000
Q2 2019 Aug 13, 2019	SELL	$1.89 - $4.01 $54,757 - $116,177	-28,972 Reduced 72.68%	10,892 $22,000
Q1 2019 Apr 12, 2019	BUY	$1.66 - $5.9 $66,174 - $235,197	39,864 New	39,864 $143,000
Q2 2018 Jul 30, 2018	SELL	$1.77 - $2.28 $52,746 - $67,944	-29,800 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$1.77 - $2.28 $52,746 - $67,944	29,800 New	29,800 $58,000

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $59.3M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.